{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:42:01Z","timestamp":1777927321963,"version":"3.51.4"},"reference-count":29,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:p>Even though darunavir\/ritonavir (DRV\/r) has high potency and a greater genetic barrier, there are few studies on the long-term effectiveness of DRV\/r-based salvage therapy in people living with HIV (PLWH) in low and middle-income countries. This retrospective cohort study, from S\u00e3o Paulo, Brazil, included ART-experienced PLWH aged \u226518 years with virological failure (VF) who had started DRV\/r plus an optimized background regimen (OBR) between 2008 and 2012. The proportion of patients with viral load (VL) &lt;50 copies\/mL, the improved mean CD4+ T cell count and the factors associated with VF during the 144-week follow-up were assessed. The study included 173 patients with the following characteristics [median (interquartile range)]: age 48 (42 -53) years; CD4+ T cell count, 229 (89 -376) cells\/mm3; VL, 4.26 (3.70 -4.74) log10; 6 (4 -7) previous regimens; and 100 (38 -156) months of VF. After 144 weeks, 129 (75%) patients had VL&lt; 50 copies\/mL and a mean increase in the CD4+ T cell count of 190 cells\/mm3. VL&gt;100,000 copies\/mL and poor adherence were associated with VF. DRV\/r plus an OBR showed high long-term virological suppression and immunological recovery. VL&gt;100,000 copies\/mL and poor adherence were associated with VF at 144 weeks.<\/jats:p>","DOI":"10.1177\/0956462420933716","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T03:06:17Z","timestamp":1595473577000},"page":"967-975","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-term virological effectiveness with darunavir\/ritonavir-based salvage therapy in people living with HIV\/AIDS from S\u00e3o Paulo, Brazil"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2802-0981","authenticated-orcid":false,"given":"Ariane Melar\u00e9 Ramos dos","family":"Santos","sequence":"first","affiliation":[{"name":"Departamento de Mol\u00e9stias Infecciosas e Parasit\u00e1rias, Universidade de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"},{"name":"Instituto de Infectologia Em\u00edlio Ribas, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amaury Pachione","family":"Martins","sequence":"additional","affiliation":[{"name":"Instituto de Infectologia Em\u00edlio Ribas, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Juliato","sequence":"additional","affiliation":[{"name":"Instituto de Infectologia Em\u00edlio Ribas, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9rique Jos\u00e9 Farias Peixoto","family":"de Miranda","sequence":"additional","affiliation":[{"name":"Medical Affairs Group da Bayer Pharmaceuticals SA, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giselle Ibette Silva Lopez","family":"Lopes","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Retrov\u00edrus, Centro de Virologia, Instituto Adolfo Lutz, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu\u00eds Fernando de Macedo","family":"Br\u00edgido","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Retrov\u00edrus, Centro de Virologia, Instituto Adolfo Lutz, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7830-8716","authenticated-orcid":false,"given":"Jos\u00e9 Ernesto","family":"Vidal","sequence":"additional","affiliation":[{"name":"Departamento de Mol\u00e9stias Infecciosas e Parasit\u00e1rias, Universidade de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"},{"name":"Instituto de Infectologia Em\u00edlio Ribas, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,7,23]]},"reference":[{"key":"bibr1-0956462420933716","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1201533"},{"key":"bibr2-0956462420933716","unstructured":"UNAIDS.\n                      Prevention gap report 2016\n                      . Geneva: UNAIDS, 2016."},{"key":"bibr3-0956462420933716","unstructured":"WHO.\n                      HIV drug resistance report 2017\n                      . Geneva: World Health Organization, 2017."},{"key":"bibr4-0956462420933716","doi-asserted-by":"publisher","DOI":"10.2165\/11538020-000000000-00000"},{"key":"bibr5-0956462420933716","doi-asserted-by":"publisher","DOI":"10.1086\/650732"},{"key":"bibr6-0956462420933716","doi-asserted-by":"publisher","DOI":"10.1086\/595701"},{"key":"bibr7-0956462420933716","unstructured":"Minist\u00e9rio da Sa\u00fade. Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para Adultos vivendo com HIV\/Aids. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade, 2017."},{"key":"bibr8-0956462420933716","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2013.04.001"},{"key":"bibr9-0956462420933716","first-page":"63","volume":"3","author":"Biscione F","year":"2013","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"bibr10-0956462420933716","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2012.08.022"},{"key":"bibr11-0956462420933716","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2015.03.005"},{"key":"bibr12-0956462420933716","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2014.0354"},{"key":"bibr13-0956462420933716","first-page":"503","volume":"32","author":"Guimar\u00e3es LSP","year":"2012","journal-title":"Rev HCPA"},{"key":"bibr14-0956462420933716","doi-asserted-by":"crossref","first-page":"18269","DOI":"10.7448\/IAS.15.6.18269","volume":"15","author":"Sch\u00f6ntag M","year":"2012","journal-title":"J Int AIDS Soc"},{"key":"bibr15-0956462420933716","first-page":"1589","volume":"10","author":"Antinori A","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"bibr16-0956462420933716","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-015-0072-9"},{"key":"bibr17-0956462420933716","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.24585"},{"key":"bibr18-0956462420933716","first-page":"1","volume":"15","author":"Armenia D","year":"2016","journal-title":"HIV Med"},{"key":"bibr19-0956462420933716","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2010.00885.x"},{"key":"bibr20-0956462420933716","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2009.12.022"},{"key":"bibr21-0956462420933716","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2010.0059"},{"key":"bibr22-0956462420933716","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2013.02.016"},{"key":"bibr23-0956462420933716","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2017.07.005"},{"key":"bibr24-0956462420933716","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-018-5731-z"},{"key":"bibr25-0956462420933716","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-012-0168-3"},{"key":"bibr26-0956462420933716","doi-asserted-by":"publisher","DOI":"10.1089\/108729101753287685"},{"key":"bibr27-0956462420933716","unstructured":"WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV Infection: recommendations for a public health approach. Geneva: World Health Organization, 2016."},{"key":"bibr28-0956462420933716","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf (2017, accessed 8 March 2019)."},{"key":"bibr29-0956462420933716","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(14)00061-7"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0956462420933716","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0956462420933716","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0956462420933716","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:40:51Z","timestamp":1777675251000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0956462420933716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,23]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1177\/0956462420933716"],"URL":"https:\/\/doi.org\/10.1177\/0956462420933716","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,23]]}}}